What is Genome Protection?
Genome Protection, Inc. is a clinical-stage biopharmaceutical entity dedicated to pioneering medical interventions aimed at preventing and treating the multifaceted aspects of aging and age-related conditions. The company's scientific foundation is built upon profound insights into the fundamental mechanisms that drive genomic instability, immune system decline (immunosenescence), and systemic inflammation (inflammaging) as organisms age. Genome Protection is actively developing therapeutic agents designed to counteract these aging-related processes. Key among these are TLR5 agonists, entolimod and GP532, which are anticipated to bolster immune functions, particularly in elderly populations. Furthermore, the company leverages its extensive research and development capabilities to cultivate a robust pipeline of innovative small-molecule and immunotherapeutic drug candidates. These candidates are strategically designed to target the intrinsic mechanisms underlying genomic instability in somatic tissues, both during the aging process and in the progression of cancer, with a particular focus on the role of endogenous retroelements, often referred to as the 'retrobiome'.
How much funding has Genome Protection raised?
Genome Protection has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Genome Protection?
With its large-scale, late-stage funding context and a recent major strategic investment, Genome Protection is poised for significant advancement in its clinical development and commercialization efforts. The substantial capital infusion is expected to accelerate the progression of its lead drug candidates, entolimod and GP532, through late-stage clinical trials. This strategic backing also signals strong confidence from investors in the company's novel approach to tackling aging and age-related diseases by targeting fundamental biological mechanisms. Future developments will likely focus on expanding the company's pipeline, potentially through further research into the 'retrobiome' and its implications for cancer and aging, and preparing for regulatory submissions. The company's trajectory suggests a move towards becoming a key player in the burgeoning field of longevity therapeutics.
See full Genome Protection company page
